EAGAN, Minn.--(BUSINESS WIRE)--Jun 4, 2007 - Imprime PGG(TM), an
investigational new drug from Biothera that enhances the innate
immune system response, increases the effectiveness of Avastin(R)
(bevacizumab) to kill cancer cells, according to new preclinical
research presented yesterday at the 2007 American Society of
Clinical Oncology Annual Meeting in Chicago.
Researchers at the Brown Cancer Center, University of
Louisville, Kentucky, studied the synergistic effects of Imprime
PGG in combination with Avastin in a xenograft mouse model where
human ovarian cancer cells were implanted into the mice. In the
treatment group receiving both Imprime PGG and Avastin, 86% of the
mice survived 100 days compared with only 43% in the group
receiving Avastin alone.
"The combination of Imprime PGG and Avastin should be considered
as potential treatment approach in patients with VEGF-expressing
tumors and needs to be further investigated in clinical trials,"
said Carolina Salvador, M.D., a clinical instructor at the Brown
Cancer Center.
"The results are consistent with previous research demonstrating
improved outcomes for both tumor size and long-term survival when
Imprime PGG is combined with complement-activating monoclonal
antibodies," said Daniel K. Conners, president of Biothera's
Pharmaceutical Group. "Our technology has the potential to
dramatically enhance both existing and developmental drug
treatments for most major types of cancer."
The ASCO poster presentation is entitled, "Cytotoxicity of
Bevacizumab is Enhanced by Beta-glucan in Tumors Expressing
Membrane-Bound VEGF." Dr. Salvador conducted the research in
collaboration with Jun Yan, MD, Ph.D., the lead researcher at the
Tumor Immunobiology Program at the Brown Cancer Center.
About Imprime PGG(TM)
Imprime PGG is a biological response modifier that enhances
specific innate immune cell responses. Biothera has completed two
Phas
'"/>
Page: 1 2 Related medicine technology :1.
Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with
Electroporation DNA Delivery Technology and New Devices at Gene
Therapy Meeting2.
Favrille Announces Results From Study Showing Enhanced Activity
From Insect Cell-Derived Immunotherapy for Lymphoma3.
Investigational Study Evaluates the Effectiveness of Aripiprazole
in Adolescents With Schizophrenia4.
Daytrana (methylphenidate transdermal system) Provides Significant
Effectiveness in ADHD Symptom Relief in Both Boys and Girls5.
Six-Week Investigational Study In Adults With Major Depressive
Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole
Therapy With Antidepressants6.
St. Jude Study Shows Effectiveness of Peramivir in Prevention of
Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection7.
Study Supports Cost-Effectiveness of Medtronics Spasticity
Treatment for Children with Cerebral Palsy8.
FDA MedWatch: Avastin (bevacizumab) and Formation of
Tracheoesophageal Fistula in a Recent Clinical Study in Patients
with Limited-stage Small Cell Lung Cancer9.
Data Presented at AACR Meeting Shows Peregrines Selective
Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical
Cancer Models10.
Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer
Study Presented at ASCO